During Tuesday’s trading session, shares of one of the 10 leading fixed-dosage injectable manufacturers in the world hit a 20 percent upper circuit on BSE, after announcing Q4 FY25 financial results with a rise in net profit by around 7 percent QoQ and 100 percent YoY.
With a market cap of Rs. 541 crores, the shares of Venus Remedies Limited hit a 20 percent upper circuit to reach a new 52-week high at Rs. 434.7 on BSE, as against its previous closing price of Rs. 362.25. The stock has delivered positive returns of around 36 percent in one year, and has gained by over 29 percent in the last one month.
What’s the News
According to the latest regulatory filings on the stock exchanges, Venus Remedies Limited announced the financial results for Q4 FY25 on Monday after market hours. For Q4 FY25, Venus Remedies reported a consolidated revenue from operations of Rs. 195 crores, reflecting a marginal growth of around 10 percent QoQ from Rs. 177 crores in Q3 FY25, but a slight year-on-year decline of about 0.1 percent from Rs. 195.2 crores in Q4 FY24.
Net profit stood at Rs. 21 crores in Q4 FY25, marking a nearly 7 percent QoQ growth from Rs. 19.6 crores reported in the previous quarter, and an annual increase of around 100 percent from Rs. 10.5 crores in Q4 FY24.
EBITDA came in at Rs. 29 crores during Q4 FY25, indicating a rise of about 61 percent QoQ from Rs. 18 crores in Q3 FY25, and a year-on-year expansion of around 53 percent YoY compared to Rs. 19 crores in Q4 FY24. Meanwhile, EBITDA margins stood at 15 percent in Q4 FY25, an improvement from 10 percent in both Q3 FY25 and Q4 FY24.
Also read: 2,054% Profit Growth: Fertiliser stock skyrockets 14% after reporting strong Q4 results
About the company
Venus Remedies Limited is one of the handful players in the pharmaceutical sector to launch injectables globally. It has world-class manufacturing facilities in Panchkula and Baddi (in India), and an R&D centre under the name of Venus Medicine Research Centre (in India). The company is mainly engaged in I/V fluids and injectables, ceftazidime, amlodipine, gliclazide, lisinopril, and more.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
